Your browser doesn't support javascript.
loading
Expanding the genotype and phenotype spectrum of SYT1-associated neurodevelopmental disorder.
Melland, Holly; Bumbak, Fabian; Kolesnik-Taylor, Anna; Ng-Cordell, Elise; John, Abinayah; Constantinou, Panayiotis; Joss, Shelagh; Larsen, Martin; Fagerberg, Christina; Laulund, Lone Walentin; Thies, Jenny; Emslie, Frances; Willemsen, Marjolein; Kleefstra, Tjitske; Pfundt, Rolf; Barrick, Rebekah; Chang, Richard; Loong, Lucy; Alfadhel, Majid; van der Smagt, Jasper; Nizon, Mathilde; Kurian, Manju A; Scott, Daniel J; Ziarek, Joshua J; Gordon, Sarah L; Baker, Kate.
Afiliação
  • Melland H; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Bumbak F; Department of Molecular and Cellular Biochemistry, College of Arts + Sciences, Indiana University Bloomington, Bloomington, IN.
  • Kolesnik-Taylor A; MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.
  • Ng-Cordell E; MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.
  • John A; MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.
  • Constantinou P; Department of Clinical Genetics, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Joss S; Department of Clinical Genetics, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Larsen M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
  • Fagerberg C; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
  • Laulund LW; Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
  • Thies J; Department of Pediatrics, Division of Genetic Medicine, Seattle Children's Hospital, Seattle, WA.
  • Emslie F; South West Thames Regional Genetics Service and St George's University of London, London, United Kingdom.
  • Willemsen M; Radboud University Medical Center, Nijmegen, The Netherlands.
  • Kleefstra T; Radboud University Medical Center, Nijmegen, The Netherlands; Vincent van Gogh Centre for Neuropsychiatry, Venray, The Netherlands.
  • Pfundt R; Radboud University Medical Center, Nijmegen, The Netherlands.
  • Barrick R; Children's Hospital of Orange County, Orange, CA.
  • Chang R; Children's Hospital of Orange County, Orange, CA.
  • Loong L; Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Alfadhel M; Genetics and Precision Medicine department, King Abdullah Specialized Children Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; Medical Genomics Research Department, King Abdullah International Medical Research Center, Ministry of National Guard
  • van der Smagt J; Utrecht University Medical Centre, Utrecht, The Netherlands.
  • Nizon M; Service de Génétique Médicale, CHU de Nantes, INSERM, Université de Nantes, Nantes, France.
  • Kurian MA; Developmental Neurosciences Programme, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • Scott DJ; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Ziarek JJ; Department of Molecular and Cellular Biochemistry, College of Arts + Sciences, Indiana University Bloomington, Bloomington, IN.
  • Gordon SL; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Baker K; MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom; Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom. Electronic address: kate.baker@mrc-cbu.cam.ac.uk.
Genet Med ; 24(4): 880-893, 2022 04.
Article em En | MEDLINE | ID: mdl-35101335
PURPOSE: Synaptotagmin-1 (SYT1) is a critical mediator of neurotransmitter release in the central nervous system. Previously reported missense SYT1 variants in the C2B domain are associated with severe intellectual disability, movement disorders, behavioral disturbances, and electroencephalogram abnormalities. In this study, we expand the genotypes and phenotypes and identify discriminating features of this disorder. METHODS: We describe 22 individuals with 15 de novo missense SYT1 variants. The evidence for pathogenicity is discussed, including the American College of Medical Genetics and Genomics/Association for Molecular Pathology criteria, known structure-function relationships, and molecular dynamics simulations. Quantitative behavioral data for 14 cases were compared with other monogenic neurodevelopmental disorders. RESULTS: Four variants were located in the C2A domain with the remainder in the C2B domain. We classified 6 variants as pathogenic, 4 as likely pathogenic, and 5 as variants of uncertain significance. Prevalent clinical phenotypes included delayed developmental milestones, abnormal eye physiology, movement disorders, and sleep disturbances. Discriminating behavioral characteristics were severity of motor and communication impairment, presence of motor stereotypies, and mood instability. CONCLUSION: Neurodevelopmental disorder-associated SYT1 variants extend beyond previously reported regions, and the phenotypic spectrum encompasses a broader range of severities than initially reported. This study guides the diagnosis and molecular understanding of this rare neurodevelopmental disorder and highlights a key role for SYT1 function in emotional regulation, motor control, and emergent cognitive function.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sinaptotagmina I / Transtornos do Neurodesenvolvimento / Deficiência Intelectual / Transtornos dos Movimentos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sinaptotagmina I / Transtornos do Neurodesenvolvimento / Deficiência Intelectual / Transtornos dos Movimentos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article